Lowest Price Guaranteed
Pages
240
Last Updated
July 2026
View Count
13926
Chapter 2 is an executive summary of the insights captured in our research. The summary offers a high level view on the likely evolution of novel RA drugs in the coming decade.
Chapter 3 provides a general introduction to RA, highlighting all associated symptoms and complications. It also includes a detailed classification and overview of mechanisms of action of the various therapeutic interventions that are currently available for the treatment of RA. These include both conventional and emerging therapies.
Chapter 4 provides a comprehensive overview of the current landscape of the RA market. It includes information on over 80 molecules that fall under non-TNF inhibitor drug classes. Some of these are approved and already available in different regions across the globe. The rest are currently in various stages of preclinical / clinical development. The chapter presents an analysis of the pipeline molecules on the basis of their current phase of development, respective mechanisms of action, route of administration, type of therapy, type of molecule and key players involved in their development. It also provides a list of potential candidates for the treatment of RA based on their respective mechanisms of action.
Chapter 5 provides a brief introduction to the novel interventions that are currently being investigated as potential treatment options for RA. It provides information on their respective mechanisms of action and lists the pipeline molecules that are being developed under each drug class.
Chapter 6 contains detailed profiles of the recently approved and late stage (phase III and above) JAK inhibitors. Each profile features a general overview of the drug and provides information on additional aspects, such as recent sales (for marketed drugs), information on clinical trials and key trial endpoints, clinical trial results, a brief history of the developer, and the collaborations and partnerships that have been inked related to the particular drug / drug candidate.
Chapter 7 contains detailed profiles of late stage (phase III and above) anti-ILs. Each profile features a general overview of the drug and provides information on additional aspects, such as recent sales (for marketed drugs), information on clinical trials and key trial endpoints, clinical trial results, a brief history of the developer, and the collaborations and partnerships that have been inked related to the particular drug / drug candidate.
Chapter 8 contains detailed profiles of late stage (phase III) drugs / therapies with novel mechanisms of action. Each profile features a general overview of the drug / therapy and provides information on additional aspects, such as recent sales (for marketed drugs), information on clinical trials and key trial endpoints, clinical trial results, a brief history of the developer, and the collaborations and partnerships that have been inked related to the particular drug / therapy candidate.
Chapter 9 provides a detailed analysis on the likely future size of the RA therapies market over the next decade. It presents comprehensive forecast scenarios for individual drug classes, including JAK inhibitors, anti-ILs and drugs with other novel mechanisms of action, which have molecules in late stages of development.
Chapter 10 is a compilation of certain key insights on RA therapies that we came across during the course of this study. It provides schematic representations highlighting the distribution of RA drugs by target class, type of molecule and the highest phase of development. The chapter also features an analysis of the landscape of developers (small, mid-sized and large companies) of RA drugs and the geographical presence of the most active players in this domain. It also presents a detailed comparative analysis on the key clinical trial endpoints for drugs that are marketed or are in phase III of clinical development. In addition, it includes an analysis of active comparator trials, highlighting the available drugs against which novel RA therapies are being compared in clinical trials, important primary endpoints being evaluated in the same and the scale (in terms of number of patients) of the phase III clinical program of the aforementioned drugs.
Chapter 11 presents a detailed analysis on the partnerships and agreements established between industry players in the last few years. Additionally, the chapter highlights the financial details of the agreements (wherever available). The chapter features a schematic representation of the collaborations on the basis of the year of establishment, the type of partnership model employed and the companies involved.
Chapter 12 provides an overview of emerging trends on social media related to RA drugs. It includes analytical data representing the popularity of RA drugs on Twitter from 2011 to H1-2016.
Chapter 13 summarizes the entire report. It presents the key takeaways and offers our independent opinion on the current market scenario and evolutionary trends that are likely to determine the future of this segment of the industry.
Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures in the report.
Chapter 15 is an appendix, which contains the list of companies and organizations that have been mentioned in the report.
1. Preface
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. Executive Summary
3. Introduction
3.1. Chapter Overview
3.2. Rheumatoid Arthritis: An Introduction
3.3. Rheumatoid Arthritis: Causes
3.4. Rheumatoid Arthritis: Diagnosis
3.5. Rheumatoid Arthritis: Currently Available Treatment Options
3.5.1. Analgesics
3.5.2. Non-Steroidal Anti-Inflammatory Drugs
3.5.3. Glucocorticoids
3.5.4. Disease Modifying Anti-Rheumatic Drugs
3.5.4.1. Conventional / Non-Biologic Disease Modifying Anti-Rheumatic Drugs
3.5.4.2. Biologic Disease Modifying Anti-Rheumatic Drugs
3.5.4.2.1. Tumor Necrosis Factor Inhibitors
3.5.4.2.2. Interleukin-1 Inhibitors
3.5.4.2.3. T-Cell Costimulation Inhibitors
3.5.4.2.4. B-Cell Inhibitors
3.5.4.2.5. Interleukin-6 Inhibitors
4. Market Overview
4.1. Chapter Overview
4.2. Rheumatoid Arthritis Therapeutics: Marketed and Clinical Pipeline
4.3. Rheumatoid Arthritis Therapeutics: Preclinical / Discovery Pipeline
4.4. Rheumatoid Arthritis Therapeutics: Distribution by Phase of Development
4.5. Rheumatoid Arthritis Therapeutics: Distribution by Drug Class
4.6. Rheumatoid Arthritis Therapeutics: Distribution by Route of Administration
4.7. Rheumatoid Arthritis Therapeutics: Distribution by Type of Molecule
4.8. Rheumatoid Arthritis Therapeutics: Distribution by Type of Therapy
4.9. Rheumatoid Arthritis Therapeutics: Distribution by Key Players
4.10. Rheumatoid Arthritis Therapeutics: List of Other Potential Candidates
5. Novel Drugs to Treat Rheumatoid Arthritis: Key Mechanisms of Action
5.1. Chapter Overview
5.2. Bruton's Tyrosine Kinase Inhibitors
5.3. Janus Kinase Inhibitors
5.4. Interleukin-17 Inhibitors
5.5. Granulocyte Macrophage-Colony Stimulating Factor Inhibitors
5.6. Stem Cell Therapies
5.7. Spleen Tyrosine Kinase Inhibitors
5.8. Chemokine Receptor Antagonists
5.9. Phospholipase A2 Inhibitors
5.10. Toll-Like Receptor Inhibitors
6. JAK Inhibitors
6.1. Chapter Overview
6.2. Xeljanz / Tofacitinib (Pfizer)
6.2.1. Overview
6.2.2. Dosage Form, Regimen and Pricing
6.2.3. Historical Sales
6.2.4. Clinical Studies
6.2.5. Key Clinical Trial Results
6.2.5.1. Monotherapy
6.2.5.1.1. Oral Start
6.2.5.1.2. Oral Solo
6.2.5.2. Add-On / Combination Therapy
6.2.5.2.1. Oral Standard
6.2.5.2.2. Oral Step
6.2.5.2.3. Oral Scan
6.2.5.2.4. Oral Sync
6.2.6. Developer Overview (Pfizer)
6.2.6.1. Financial Performance
6.2.6.2. Collaborations
6.3. Baricitinib (Eli Lilly / Incyte Corporation)
6.3.1. Overview
6.3.2. Clinical Studies
6.3.3. Key Clinical Trial Results
6.3.3.1. Monotherapy / Add-On Therapy
6.3.3.1.1. RA-BEGIN
6.3.3.1.2. RA-BEYOND
6.3.3.2. Add-On / Combination Therapy
6.3.3.2.1. RA-BEAM
6.3.3.2.2. RA-BUILD
6.3.3.2.3. RA-BEACON
6.3.4. Developer Overview (Incyte Corporation / Eli Lilly)
6.3.4.1. Financial Performance
6.3.4.2. Collaborations
6.4. Filgotinib / GLPG0634 (Galapagos / Gilead Sciences)
6.4.1. Overview
6.4.2. Clinical Studies
6.4.3. Key Clinical Trial Results
6.4.3.1. Monotherapy
6.4.3.1.1. DARWIN 2
6.4.3.2. Add-on Therapy
6.4.3.2.1. DARWIN 1
6.4.3.2.2. NCT01384422
6.4.4. Developer Overview (Galapagos / Gilead Sciences)
6.4.4.1. Financial Performance
6.4.4.2. Collaborations
6.5. Peficitinib (Astellas Pharma)
6.5.1. Overview
6.5.2. Clinical Studies
6.5.3. Key Clinical Trial Results
6.5.3.1. Monotherapy
6.5.3.2. Add-On / Combination Therapy
6.5.4. Developer Overview (Astellas Pharma)
6.5.4.1. Financial Performance
6.5.4.2. Collaborations
6.6. Upadacitinib / ABT-494 (AbbVie)
6.6.1. Overview
6.6.2. Clinical Studies
6.6.3. Key Clinical Trial Results
6.6.3.1. Add-On Therapy / Combination Therapy
6.6.3.1.1. BALANCE-I
6.6.3.1.2. BALANCE-II
6.6.4. Developer Overview (AbbVie)
6.6.4.1. Financial Performance
7. Interleukin-6 Inhibitors
7.1. Chapter Overview
7.2. Sarilumab (Sanofi / Regeneron Pharmaceuticals)
7.2.1. Overview
7.2.2. Clinical Studies
7.2.3. Key Clinical Trial Results
7.2.3.1. Monotherapy
7.2.3.1.1. SARIL-RA-MONARCH
7.2.3.2. Add-On / Combination Therapy
7.2.3.2.1. SARIL-RA-MOBILITY
7.2.3.2.2. SARIL-RA-TARGET
7.2.3.2.3. SARIL-RA-ASCERTAIN
7.2.4. Developer Overview (Sanofi / Regeneron Pharmaceuticals)
7.2.4.1. Financial Performance
7.2.4.2. VelocImmune
7.2.4.3. Collaborations
7.3. Sirukumab (Johnson & Johnson / GSK)
7.3.1. Overview
7.3.2. Clinical Studies
7.3.3. Key Clinical Trial Results
7.3.3.1. SIRROUND-D
7.3.3.2. SIRROUND-H and SIRROUND-T Results
7.3.4. Developer Overview (Johnson & Johnson / GSK)
7.3.4.1. Financial Performance
7.3.4.2. Collaborations
8. Novel Drugs for Rheumatoid Arthritis
8.1. Chapter Overview
8.2. Piclidenoson / CF101 (Can-Fite Biopharma)
8.2.1. Overview
8.2.2. Clinical Studies
8.2.3. Key Clinical Trial Results
8.2.4. Developer Overview (Can-Fite Biopharma)
8.2.4.1. Financial Performance
8.2.4.2. Collaborations
8.3. Ravax™ (Immune Response BioPharma)
8.3.1. Overview
8.3.2. Clinical Studies
8.3.3. Key Clinical Trial Results
8.3.4. Developer Overview (Immune Response BioPharma)
9. Market Forecast
9.1. Chapter Overview
9.2. Forecast Methodology
9.3. Scope and Key Assumptions
9.4. Overall DMARDs Market for Rheumatoid Arthritis, 2016-2026 (USD Billion)
9.5. Overall JAK Inhibitors Market, 2016-2026 (USD Billion)
9.5.1. Xeljanz / Tofacitinib (USD Million)
9.5.2. Baricitinib (USD Million)
9.5.3. Filgotinib (USD Million)
9.5.4. Peficitinib / ASP015K (USD Million)
9.5.5. Upadacitinib / ABT-494 (USD Million)
9.6. Overall Non-TNF Biologics Market, 2016-2026 (USD Billion)
9.6.1. Actemra / Roactemra / Tocilizumab / (USD Million)
9.6.2. Kineret / Anakinra (USD Million)
9.6.3. Orencia / Abatacept (USD Million)
9.6.4. Rituxan / MabThera / Rituximab (USD Million)
9.6.5. Sarilumab (USD Million)
9.6.6. Sirukumab (USD Million)
9.6.7. Ravax™ (USD Million)
9.7. Overall Other Novel Oral Therapies Market, 2016-2026 (USD Billion)
9.7.1. Piclidenoson / CF-101 (USD Million)
10. Key Insights
10.1. Chapter Overview
10.2. Rheumatoid Arthritis Therapeutics Clinical Development Analysis: Pipeline Analysis
10.3. Rheumatoid Arthritis Therapeutics Clinical Development Analysis: Developer Landscape
10.4. Rheumatoid Arthritis Therapeutics Clinical Development Analysis: Regional Distribution
10.5. Rheumatoid Arthritis Therapeutics Clinical Development Analysis: Active Comparator Trial Comparison
10.6. Rheumatoid Arthritis Therapeutics Clinical Development Analysis: Patient Size Comparison
10.7. Rheumatoid Arthritis Therapeutics Clinical Development Analysis: Primary Endpoint Comparison
11. Recent Collaborations
11.1. Chapter Overview
11.2. Partnership Models / Agreements
11.3. Rheumatoid Arthritis: Recent Collaborations
11.3.1. Rheumatoid Arthritis: Mapping Collaborations
11.3.2. Rheumatoid Arthritis: Distribution of Partnerships by Year
11.3.3. Rheumatoid Arthritis: Distribution of Partnerships by Type of Model
11.3.4. Rheumatoid Arthritis: Distribution of Partnerships by Molecule
11.3.5. Rheumatoid Arthritis: Leading Collaborators
12. Emerging Trends on Social Media
12.1. Chapter Overview
12.2. Trends on Twitter
12.2.1. Rheumatoid Arthritis: Yearly Distribution of Tweets
12.2.2. Rheumatoid Arthritis: Highlights on Twitter
12.2.3. Rheumatoid Arthritis: Most Popular Drug Classes
13. Conclusion
13.1. Post the Paradigm Shift from Analgesics to Biologic DMARDS, the Rheumatoid Arthritis Market Continues to Evolve with the Emergence of Multiple Novel Drug Classes
13.2. With Five Marketed Product Candidates and Several Clinical and Preclinical Molecules, the non-TNF Inhibitors Pipeline Holds Significant Future Potential
13.3. Anti-Interleukins and JAK Inhibitors Have Emerged as Potential Therapeutic Options; BTK Inhibitors, SYK Inhibitors and GM-CSF Inhibitors are Amongst the Popular Novel Drug Classes Under Development
13.4. Emergence of Innovative Strategies Has Led to the Development of Stem Cell Therapies, Gene Therapies and Vaccines for the Treatment of RA
13.5. Oral Therapies are Likely to Emerge as Key Contributors in the Near Future
13.6. Combination Therapies Have been Shown to Offer Increased Health Benefits while Minimizing Adverse Effects Associated with Individual Therapeutic Classes
13.7. Big Pharmaceutical Companies Dominate the Current Rheumatoid Arthritis Space; Several Start-Ups / Small Companies Have Emerged
13.8. The Expected Launch of Late-Phase JAK Inhibitors and Anti-Interleukins in the Near Future is Likely to Intensify the Competition�
14. Appendix 1: Tabulated Data
15. Appendix 2: List of Companies and Organizations
Figure 3.1 Rheumatoid Arthritis: Currently Available Treatment Options
Figure 3.2 Therapeutic Interventions for Rheumatoid Arthritis: Marketed Analgesics
Figure 3.3 Therapeutic Interventions for Rheumatoid Arthritis: Marketed NSAIDs
Figure 3.4 Therapeutic Interventions for Rheumatoid Arthritis: Conventional / Non-Biologic DMARDs
Figure 3.5 Classification of Biologic DMARDs for Rheumatoid Arthritis Based on Mechanism of Action
Figure 4.1 Rheumatoid Arthritis Therapeutics: Distribution by Phase of Development
Figure 4.2 Rheumatoid Arthritis Therapeutics: Distribution by Drug Class
Figure 4.3 Rheumatoid Arthritis Therapeutics: Distribution by Route of Administration
Figure 4.4 Rheumatoid Arthritis Therapeutics: Distribution by Type of Molecule
Figure 4.5 Rheumatoid Arthritis Therapeutics: Distribution by Type of Therapy
Figure 4.6 Rheumatoid Arthritis Therapeutics: Distribution by Key Players
Figure 6.1 Tofacitinib: Historical Sales, FY2013 - Q3 FY2016 (USD Million)
Figure 6.2 Tofacitinib: Phase III Clinical Development Program
Figure 6.3 Tofacitinib as Add-On Therapy: Clinical Trial Results, ACR and DAS28-4 (ESR) Scores (% of Patients)
Figure 6.4 Tofacitinib as Add-On Therapy: Clinical Trial Results, Change from Baseline in HAQ-DI
Figure 6.5 Pfizer: Revenues, FY2011-Q3 FY 2016 (USD Billion)
Figure 6.6 Baricitinib: Phase III Clinical Development Program
Figure 6.7 Baricitinib: Clinical Trials Results, ACR Scores (% of Patients)
Figure 6.8 Incyte Corporation: Revenues, FY 2011-Q3 FY 2016 (USD Million)
Figure 6.9 Eli Lilly: Revenues, FY 2011–Q3 FY 2016 (USD Billion)
Figure 6.10 Filgotinib: Phase III Clinical Development Program
Figure 6.11 Filgotinib: Clinical Trial Results, ACR Scores (% of Patients)
Figure 6.12 Galapagos: Revenues, FY 2012-Q3 FY2016 (EUR Million)
Figure 6.13 Gilead Sciences: Revenues, FY 2011–Q3 FY 2016 (USD Billion)
Figure 6.14 Peficitinib: Phase III Clinical Development Program
Figure 6.15 Peficitinib: Clinical Trial Results, ACR Scores (% of Patients)
Figure 6.16 Astellas Pharma: Revenues, FY2011-Q2 FY2016 (JPY Billion)
Figure 6.17 Upadacitinib: Phase III Clinical Development Program
Figure 6.18 Upadacitinib: Clinical Trial Results, ACR Scores (% of Patients)
Figure 6.19 AbbVie: Revenues, FY 2011-Q3 2016 (USD Billion)
Figure 7.1 Sarilumab: Phase III Clinical Development Program
Figure 7.2 Sarilumab: Clinical Trials Results, ACR Scores (% of Patients)
Figure 7.3 Sarilumab: Clinical Trials Results, Change in HAQ-DI Scores
Figure 7.4 Regeneron Pharmaceuticals: Revenues, FY2011-Q3 FY2016 (USD Billion)
Figure 7.5 Sanofi: Revenues, FY2011-Q3 FY2016 (EUR Billion)
Figure 7.6 Sirukumab: Phase III Clinical Development Program
Figure 7.7 Johnson & Johnson: Revenues, FY2011-Q3 FY2016 (USD Billion)
Figure 7.8 GSK: Revenues, FY2011-Q3 FY2016 (GBP Billion)
Figure 9.1 Rheumatoid Arthritis DMARDs Market (USD Billion), 2016-2026 (Base Scenario)
Figure 9.2 Rheumatoid Arthritis DMARDs Market (USD Billion), 2016, 2021 and 2026 (Base Scenario): Distribution by Type of Drug Class
Figure 9.3 JAK Inhibitors Market (USD Billion), 2016-2026 (Base Scenario)
Figure 9.4 Xeljanz® / Tofacitinib Sales Forecast (USD Million), 2016-2026 (Base Scenario)
Figure 9.5 Baricitinib Sales Forecast (USD Million), 2017-2026 (Base Scenario)
Figure 9.6 Filgotinib Sales Forecast (USD Million), 2019-2026 (Base Scenario)
Figure 9.7 Peficitinib / ASP015K Sales Forecast (USD Million), 2018-2026 (Base Scenario)
Figure 9.8 Upadacitinib / ABT-494 Sales Forecast (USD Million), 2019-2026 (Base Scenario)
Figure 9.9 Non-TNF Biologics Market (USD Billion), 2016-2026 (Base Scenario)
Figure 9.10 Actemra® / Roactemra® / Tocilizumab Sales Forecast (USD Million), 2016-2026 (Base Scenario)
Figure 9.11 Kineret® / Anakinra Sales Forecast (USD Million), 2016-2026 (Base Scenario)
Figure 9.12 Orencia® / Abatacept Sales Forecast (USD Million), 2016-2026 (Base Scenario)
Figure 9.13 Rituxan® / MabThera®/ Rituximab Sales Forecast (USD Million), 2016-2026 (Base Scenario)
Figure 9.14 Sarilumab Sales Forecast (USD Million), 2017-2026 (Base Scenario)
Figure 9.15 Sirukumab Sales Forecast (USD Million), 2017-2026 (Base Scenario)
Figure 9.16 Ravax™ Sales Forecast (USD Million), 2017-2026 (Base Scenario)
Figure 9.17 Overall Other Novel Oral Therapies Market (USD Billion), 2018-2026 (Base Scenario)
Figure 9.18 Piclidenoson Sales Forecast (USD Million), 2018-2026 (Base Scenario)
Figure 10.1 Rheumatoid Arthritis Therapeutics Grid Analysis: Distribution by Drug Class, Type of Molecule and Phase of Development
Figure 10.2 Rheumatoid Arthritis Therapeutics Developer Landscape: Distribution by Developer and Phase of Development
Figure 10.3 Rheumatoid Arthritis Therapeutics Regional Analysis: Distribution by Company Location and Phase of Development
Figure 10.4 Rheumatoid Arthritis Therapeutics Clinical Trial Analysis: Distribution by Active Comparator
Figure 10.5 Rheumatoid Arthritis Therapeutics Clinical Trial Analysis: Distribution by Scale of Phase III Program
Figure 10.6 Rheumatoid Arthritis Therapeutics Clinical Development Analysis: Distribution by Primary Endpoints
Figure 11.1 Rheumatoid Arthritis Therapeutics Collaboration Landscape: Distribution by Collaborators, Type and Year of Collaboration
Figure 11.2 Rheumatoid Arthritis: Cumulative Distribution of Partnerships by Year
Figure 11.3 Rheumatoid Arthritis: Distribution of Partnerships by Type of Model
Figure 11.4 Rheumatoid Arthritis: Distribution of Partnerships by Molecules
Figure 11.5 Rheumatoid Arthritis: Leading Collaborators
Figure 12.1 Rheumatoid Arthritis Social Media Analysis: Yearly Distribution of Tweets, January 2013 - July 2016
Figure 12.2 Rheumatoid Arthritis Social Media Analysis: Highlights on Twitter, January 2013- July 2016
Figure 12.3 Rheumatoid Arthritis Social Media Analysis: Twitter, Most Popular Drug Classes, January 2013- July 2016
Figure 13.1 Overall Rheumatoid Arthritis DMARDs Market Forecast (USD Billion), 2016-2026: Distribution by Drug Class
Table 3.1 ACR-EULAR Classification Criteria for Rheumatoid Arthritis
Table 3.2 Therapeutic Interventions for Rheumatoid Arthritis: Marketed Corticosteroids
Table 3.3 Therapeutic Interventions for Rheumatoid Arthritis: Marketed Biologics
Table 4.1 Rheumatoid Arthritis Therapeutics: Marketed and Clinical Pipeline
Table 4.2 Rheumatoid Arthritis Therapeutics: Preclinical Pipeline
Table 4.3 Rheumatoid Arthritis Therapeutics: List of Potential Candidates
Table 5.1 Key Mechanisms of Action: List of Drugs Under Development
Table 6.1 Tofacitinib: Clinical Trials
Table 6.2 Tofacitinib: Clinical Trial Endpoints, Phase IV Trials
Table 6.3 Tofacitinib as Monotherapy: Clinical Trial Endpoints, Phase III Trials
Table 6.4 Tofacitinib as an Add-On Therapy: Clinical Trial Endpoints, Phase III Studies
Table 6.5 ORAL Start: Clinical Trial Results
Table 6.6 ORAL Solo: Clinical Trial Results
Table 6.7 ORAL Standard: Clinical Trial Results
Table 6.8 Oral Step: Clinical Trial Results
Table 6.9 ORAL Scan: Clinical Trial Results
Table 6.10 ORAL SYNC: Clinical Trial Results
Table 6.11 Baricitinib: Clinical Trials
Table 6.12 Baricitinib: Clinical Trial Endpoints
Table 6.13 RA-BEGIN: Clinical Trial Results
Table 6.14 RA-BEAM: Clinical Trial Results
Table 6.15 RA-BUILD: Clinical Trial Results
Table 6.16 RA-BEACON: Clinical Trial Results
Table 6.17 Filgotinib: Clinical Trials
Table 6.18 Filgotinib: Clinical Trial Endpoints
Table 6.19 DARWIN-2: Clinical Trial Results
Table 6.20 DARWIN-1: Clinical Trial Results
Table 6.21 NCT01384422: Clinical Trial Results
Table 6.22 Peficitinib: Clinical Trials
Table 6.23 Peficitinib: Clinical Trial Endpoints
Table 6.24 NCT01649999: Clinical Trial Results
Table 6.25 NCT01565655: Clinical Trial Results
Table 6.26 NCT01554696 Clinical Trial Results
Table 6.27 Upadacitinib: Clinical Trials
Table 6.28 Upadacitinib: Clinical Trial Endpoints
Table 6.29 BALANCE I: Clinical Trial Results
Table 6.30 BALANCE II: Clinical Trial Results
Table 7.1 Sarilumab: Clinical Trials
Table 7.2 Sarilumab as Monotherapy: Clinical Trial Endpoints
Table 7.3 Sarilumab as Add-On / Combination Therapy: Clinical Trial Endpoints
Table 7.4 SARIL-RA-MONARCH: Clinical Trial Results
Table 7.5 SARIL-RA-MOBILITY: Clinical Trial Results
Table 7.6 SARIL-RA-TARGET: Clinical Trial Results
Table 7.7 SARIL-RA-ASCERTAIN: Clinical Trial Results
Table 7.8 Sirukumab: Clinical Trials
Table 7.9 Sirukumab: Clinical Trial Endpoints
Table 7.10 SIRROUND-D: Clinical Trial Results
Table 8.1 Piclidenoson: Clinical Trials
Table 8.2 Piclidenoson: Clinical Trial Endpoints
Table 8.3 Ravax™: Clinical Trials
Table 8.4 Ravax™: Clinical Trial Endpoints
Table 9.1 Rheumatoid Arthritis Therapeutics Market: List of Forecasted Molecules
Table 9.2 Non-TNF Biologics: Molecules in Early / Mid-Stage Clinical Development
Table 9.3 Novel Oral Therapies: Molecules in Early / Mid-Stage Clinical Development
Table 11.1 Rheumatoid Arthritis: Recent Collaborations
Table 14.1 Rheumatoid Arthritis Therapeutics: Distribution by Phase of Development
Table 14.2 Rheumatoid Arthritis Therapeutics: Distribution by Drug Class
Table 14.3 Rheumatoid Arthritis Therapeutics: Distribution by Route of Administration
Table 14.4 Rheumatoid Arthritis Therapeutics: Distribution by Type of Molecule
Table 14.5 Rheumatoid Arthritis Therapeutics: Distribution by Type of Therapy
Table 14.6 Rheumatoid Arthritis Therapeutics: Distribution by Key Player
Table 14.7 Tofacitinib: Historical Sales, FY2013-Q3 FY 2016 (USD Million)
Table 14.8 Pfizer: Revenues, FY2011-Q3 FY2016 (USD Billion)
Table 14.9 Incyte Corporation: Revenues, FY2011-Q3 FY2016 (USD Million)
Table 14.10 Eli Lilly: Revenues, FY2011-Q3 FY2016 (USD Billion)
Table 14.11 Galapagos: Revenues, FY2012-Q3 FY2016 (EUR Million)
Table 14.12 Gilead Sciences: Revenues, FY2011-Q3 FY2016 (USD Billion)
Table 14.13 Astellas Pharma: Revenues, FY2011-Q2 FY2016 (JPY Billion)
Table 14.14 AbbVie: Revenues, FY2011-Q3 FY2016 (USD Billion)
Table 14.15 Regeneron Pharmaceuticals: Revenues, FY2011-Q3 FY2016 (USD Billion)
Table 14.16 Sanofi: Revenues, FY2011-Q3 FY2016 (EUR Billion)
Table 14.17 Johnson & Johnson: Revenues, FY2011-Q3 FY2016 (USD Billion)
Table 14.18 GSK: Revenues, FY2011-Q3 FY2016 (GBP Billion)
Table 14.19 Rheumatoid Arthritis DMARDs Market (USD Billion), 2016-2026 (Optimistic Scenario)
Table 14.20 Rheumatoid Arthritis DMARDs Market (USD Billion), 2016-2026 (Base Scenario)
Table 14.21 Rheumatoid Arthritis DMARDs Market (USD Billion), 2016-2026 (Conservative Scenario)
Table 14.22 Rheumatoid Arthritis DMARDs Market (USD Billion), 2016, 2021 and 2026 (Optimistic Scenario): Distribution by Type of Drug Class
Table 14.23 Rheumatoid Arthritis DMARDs Market (USD Billion), 2016, 2021 and 2026 (Base Scenario): Distribution by Type of Drug Class
Table 14.24 Rheumatoid Arthritis DMARDs Market (USD Billion), 2016, 2021 and 2026 (Conservative Scenario): Distribution by Type of Drug Class
Table 14.25 JAK Inhibitors Market (USD Billion), 2016-2026 (Optimistic Scenario)
Table 14.26 JAK Inhibitors Market (USD Billion), 2016-2026 (Base Scenario)
Table 14.27 JAK Inhibitors Market (USD Billion), 2016-2026 (Conservative Scenario)
Table 14.28 Xeljanz® / Tofacitinib Sales Forecast (USD Million), 2016-2026 (Optimistic Scenario)
Table 14.29 Xeljanz® / Tofacitinib Sales Forecast (USD Million), 2017-2026 (Base Scenario)
Table 14.30 Xeljanz® / Tofacitinib Sales Forecast (USD Million), 2017-2026 (Conservative Scenario)
Table 14.31 Baricitinib Sales Forecast (USD Million), 2017-2026 (Optimistic Scenario)
Table 14.32 Baricitinib Sales Forecast (USD Million), 2017-2026 (Base Scenario)
Table 14.33 Baricitinib Sales Forecast (USD Million), 2017-2026 (Conservative Scenario)
Table 14.34 Filgotinib Sales Forecast (USD Million), 2019-2026 (Optimistic Scenario)
Table 14.35 Filgotinib Sales Forecast (USD Million), 2019-2026 (Base Scenario)
Table 14.36 Filgotinib Sales Forecast (USD Million), 2019-2026 (Conservative Scenario)
Table 14.37 Peficitinib Sales Forecast (USD Million), 2018-2026 (Optimistic Scenario)
Table 14.38 Peficitinib Sales Forecast (USD Million), 2018-2026 (Base Scenario)
Table 14.39 Peficitinib Sales Forecast (USD Million), 2018-2026 (Conservative Scenario)
Table 14.40 Upadacitinib / ABT-494 Sales Forecast (USD Million), 2019-2026 (Optimistic Scenario)
Table 14.41 Upadacitinib / ABT-494 Sales Forecast (USD Million), 2019-2026 (Base Scenario)
Table 14.42 Upadacitinib / ABT-494 Sales Forecast (USD Million), 2019-2026 (Conservative Scenario)
Table 14.43 Non-TNF Biologics Market (USD Billion), 2016-2026 (Optimistic Scenario)
Table 14.44 Non-TNF Biologics Market (USD Billion), 2016-2026 (Base Scenario)
Table 14.45 Non-TNF Biologics Market (USD Billion), 2016-2026 (Conservative Scenario)
Table 14.46 Actemra® / Roactemra® / Tocilizumab Sales Forecast (USD Million), 2016-2026 (Optimistic Scenario)
Table 14.47 Actemra® / Roactemra® / Tocilizumab Sales Forecast (USD Million), 2016-2026 (Base Scenario)
Table 14.48 Actemra® / Roactemra® / Tocilizumab Sales Forecast (USD Million), 2016-2026 (Conservative Scenario)
Table 14.49 Kineret® / Anakinra Sales Forecast (USD Million), 2016-2026 (Optimistic Scenario)
Table 14.50 Kineret® / Anakinra Sales Forecast (USD Million), 2016-2026 (Base Scenario)
Table 14.51 Kineret® / Anakinra Sales Forecast (USD Million), 2016-2026 (Conservative Scenario)
Table 14.52 Orencia® / Abatacept Sales Forecast (USD Million), 2016-2026 (Optimistic Scenario)
Table 14.53 Orencia® / Abatacept Sales Forecast (USD Million), 2016-2026 (Base Scenario)
Table 14.54 Orencia® / Abatacept Sales Forecast (USD Million), 2016-2026 (Conservative Scenario)
Table 14.55 Rituxan® / MabThera® / Rituximab Sales Forecast (USD Million), 2016-2026 (Optimistic Scenario)
Table 14.56 Rituxan® / MabThera® / Rituximab Sales Forecast (USD Million), 2016-2026 (Base Scenario)
Table 14.57 Rituxan® / MabThera® / Rituximab Sales Forecast (USD Million), 2016-2026 (Conservative Scenario)
Table 14.58 Sarilumab Sales Forecast (USD Million), 2017-2026 (Optimistic Scenario)
Table 14.59 Sarilumab Sales Forecast (USD Million), 2017-2026 (Base Scenario)
Table 14.60 Sarilumab Sales Forecast (USD Million), 2017-2026 (Conservative Scenario)
Table 14.61 Sirukumab Sales Forecast (USD Million), 2017-2026 (Optimistic Scenario)
Table 14.62 Sirukumab Sales Forecast (USD Million), 2017-2026 (Base Scenario)
Table 14.63 Sirukumab Sales Forecast (USD Million), 2017-2026 (Conservative Scenario)
Table 14.64 Ravax™ Sales Forecast (USD Million), 2017-2026 (Optimistic Scenario)
Table 14.65 Ravax™ Sales Forecast (USD Million), 2017-2026 (Base Scenario)
Table 14.66 Ravax™ Sales Forecast (USD Million), 2017-2026 (Conservative Scenario)
Table 14.67 Overall Other Novel Oral Therapies Market (USD Billion), 2020-2026 (Optimistic Scenario)
Table 14.68 Overall Other Novel Oral Therapies Market (USD Billion), 2020-2026 (Base Scenario)
Table 14.69 Overall Other Novel Oral Therapies Market (USD Billion), 2020-2026 (Conservative Scenario)
Table 14.70 Piclidenoson Sales Forecast (USD Million), 2018-2026 (Optimistic Scenario)
Table 14.71 Piclidenoson Sales Forecast (USD Million), 2018-2026 (Base Scenario)
Table 14.72 Piclidenoson Sales Forecast (USD Million), 2018-2026 (Conservative Scenario)
Table 14.73 Rheumatoid Arthritis: Cumulative Distribution of Partnerships by Year
Table 14.74 Rheumatoid Arthritis: Distribution of Partnerships by Type of Model
Table 14.75 Rheumatoid Arthritis: Distribution of Partnerships by Molecule
Table 14.76 Rheumatoid Arthritis: Leading Collaborators
Table 14.77 Overall Rheumatoid Arthritis DMARDs Market Forecast (USD Billion), 2016-2026: Distribution by Drug Class (Optimistic Scenario)
Table 14.78 Overall Rheumatoid Arthritis DMARDs Market Forecast (USD Billion), 2016-2026: Distribution by Drug Class (Base Scenario)
Table 14.79 Overall Rheumatoid Arthritis DMARDs Market Forecast (USD Billion), 2016-2026: Distribution by Drug Class (Conservative Scenario)
The following companies and organizations have been mentioned in the report.